Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Children and Young Adults With Relapsed/Refractory Solid Tumors
NCT01502410Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2012
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of sorafenib in rhabdomyosarcoma (RMS), Wilms' tumor, hepatocellular carcinoma (HCC) and 1 more (4 arms), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate. Started Jan 2012; status: completed.
02
Drugs
sorafenib
03
Conditions
rhabdomyosarcoma (RMS)Wilms' tumorhepatocellular carcinoma (HCC)Papillary Thyroid Carcinoma (PTC)
Beyond the preview
Go deeper on NCT01502410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01502410.